Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms

REFERENCES

1. 1.↵
   1. Agmon-Levin N,
   2. Damoiseaux J,
   3. Kallenberg C,
   4. Sack U,
   5. Witte T,
   6. Herold M,
   7. et al.

   International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17–23.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Ochs RL,
   2. Mahler M,
   3. Basu A,
   4. Rios-Colon L,
   5. Sanchez TW,
   6. Andrade LE,
   7. et al.

   The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med 2016;16:273–93.

   OpenUrlCrossRef
3. 3.↵
   1. Chan EK,
   2. Damoiseaux J,
   3. de Melo Cruvinel W,
   4. Carballo OG,
   5. Conrad K,
   6. Francescantonio PL,
   7. et al.

   Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 2016;25:797–804.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Damoiseaux J,
   2. von Muhlen CA,
   3. Garcia-De La Torre I,
   4. Carballo OG,
   5. de Melo Cruvinel W,
   6. Francescantonio PL,
   7. et al.

   International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights 2016;7:1.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Miyara M,
   2. Albesa R,
   3. Charuel JL,
   4. El Amri M,
   5. Fritzler MJ,
   6. Ghillani-Dalbin P,
   7. et al.

   Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol 2013;2013:703759.

   OpenUrlPubMed
6. 6.↵
   1. Bizzaro N,
   2. Tonutti E,
   3. Tampoia M,
   4. Infantino M,
   5. Cucchiaro F,
   6. Pesente F,
   7. et al;
   8. Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine

   . Specific chemoluminescence and immunoasdorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta 2015;451:271–7.

   OpenUrl
7. 7.↵
   1. Mahler M,
   2. Parker T,
   3. Peebles CL,
   4. Andrade LE,
   5. Swart A,
   6. Carbone Y,
   7. et al.

   Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104–10.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Mariz HA,
   2. Sato EI,
   3. Barbosa SH,
   4. Rodrigues SH,
   5. Dellavance A,
   6. Andrade LE

   . Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191–200.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Muro Y,
   2. Sugiura K,
   3. Morita Y,
   4. Tomita Y

   . High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 2008;17:171–6.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Bentow C,
    2. Fritzler MJ,
    3. Mummert E,
    4. Mahler M

    . Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 2016;7:8.

    OpenUrl
11. 11.↵
    1. Gundín S,
    2. Irure-Ventura J,
    3. Asensio E,
    4. Ramos D,
    5. Mahler M,
    6. Martínez-Taboada V,
    7. et al.

    Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Auto Immun Highlights 2016;7:10.

    OpenUrl
12. 12.↵
    1. Shovman O,
    2. Gilburd B,
    3. Chayat C,
    4. Amital H,
    5. Langevitz P,
    6. Watad A,
    7. et al.

    Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol 2018;36:121–6.

    OpenUrl
13. 13.↵
    1. Watanabe A,
    2. Kodera M,
    3. Sugiura K,
    4. Usuda T,
    5. Tan EM,
    6. Takasaki Y,
    7. et al.

    Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892–900.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Clegg DO,
    2. Williams HJ,
    3. Singer JZ,
    4. Steen VD,
    5. Schlegel S,
    6. Ziminski C,
    7. et al.

    Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340–3.

    OpenUrlPubMed
15. 15.↵
    1. Mosca M,
    2. Neri R,
    3. Bombardieri S

    . Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999;17:615–20.

    OpenUrlPubMed
16. 16.↵
    1. Mosca M,
    2. Tani C,
    3. Carli L,
    4. Bombardieri S

    . Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol 2012;26:73–7.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Doria A,
    2. Mosca M,
    3. Gambari PF,
    4. Bombardieri S

    . Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol 2005;32:213–5.

    OpenUrlFREE Full Text
18. 18.↵
    1. Petri M,
    2. Orbai AM,
    3. Alarcon GS,
    4. Gordon C,
    5. Merrill JT,
    6. Fortin PR,
    7. et al.

    Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Shiboski CH,
    2. Shiboski SC,
    3. Seror R,
    4. Criswell LA,
    5. Labetoulle M,
    6. Lietman TM,
    7. et al;
    8. International Sjögren’s Syndrome Criteria Working Group

    . 2016 American College of Rheumatology/European League Against rheumatism classification criteria for primary Sjogren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017;69:35–45.

    OpenUrlPubMed
20. 20.↵
    1. van den Hoogen F,
    2. Khanna D,
    3. Fransen J,
    4. Johnson SR,
    5. Baron M,
    6. Tyndall A,
    7. et al.

    2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Miyakis S,
    2. Lockshin MD,
    3. Atsumi T,
    4. Branch DW,
    5. Brey RL,
    6. Cervera R,
    7. et al.

    International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. York Health Economics Consortium (YHEC)

    . Decision tree. [Internet. Accessed March 10, 2020.] Available from: www.yhec.co.uk/glossary/decision-tree
23. 23.↵
    1. Mosca M,
    2. Tani C,
    3. Talarico R,
    4. Bombardieri S

    . Undifferentiated connective tissue diseases (UCTD): Simplified systemic autoimmune diseases. Autoimmun Rev 2011;10:256–8.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. York Health Economics Consortium (YHEC)

    . Sensitivity analysis. [Internet. Accessed March 10, 2020.] Available from: www.yhec.co.uk/glossary/sensitivity-analysis
25. 25.↵
    1. Fitch-Rogalsky C,
    2. Steber W,
    3. Mahler M,
    4. Lupton T,
    5. Martin L,
    6. Barr SG,
    7. et al.

    Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 2014;9:e93812.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Lom-Orta H,
    2. Alarcon-Segovia D,
    3. Diaz-Jouanen E

    . Systemic lupus erythematosus. Differences between patients who do, and who do not, fulfill classification criteria at the time of diagnosis. J Rheumatol 1980;7:831–7.

    OpenUrlPubMed
27. 27.↵
    1. Greer JM,
    2. Panush RS

    . Incomplete lupus erythematosus. Arch Intern Med 1989;149:2473–6.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Mosca M,
    2. Neri R,
    3. Bencivelli W,
    4. Tavoni A,
    5. Bombardieri S

    . Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol 2002;29:2345–9.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Swaak AJ,
    2. van de Brink H,
    3. Smeenk RJ,
    4. Manger K,
    5. Kalden JR,
    6. Tosi S,
    7. et al;
    8. Study group on incomplete SLE SLE with disease duration longer than 10 years

    . Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatol 2001;40:89–94.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Bodolay E,
    2. Csiki Z,
    3. Szekanecz Z,
    4. Ben T,
    5. Kiss E,
    6. Zeher M,
    7. et al.

    Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003;21:313–20.

    OpenUrlPubMed
31. 31.↵
    1. Danieli MG,
    2. Fraticelli P,
    3. Franceschini F,
    4. Cattaneo R,
    5. Farsi A,
    6. Passaleva A,
    7. et al.

    Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol 1999;17:585–91.

    OpenUrlPubMed
32. 32.↵
    1. Abeles AM,
    2. Abeles M

    . The clinical utility of a positive antinuclear antibody test result. Am J Med 2013;126:342–8.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Avery TY,
    2. van de Cruys M,
    3. Austen J,
    4. Stals F,
    5. Damoiseaux JG

    . Anti-nuclear antibodies in daily clinical practice: prevalence in primary, secondary, and tertiary care. J Immunol Res 2014;2014:401739.

    OpenUrl
34. 34.↵
    1. Bonroy C,
    2. Schouwers S,
    3. Berth M,
    4. Van Hoovels L

    . The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin Chem Lab Med 2019;57:e47–8.

    OpenUrl
35. 35.↵
    1. Choi MY,
    2. Clarke AE,
    3. St Pierre Y,
    4. Hanly JG,
    5. Urowitz MB,
    6. Romero-Diaz J,
    7. et al.

    The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus 2017;26:1051–9.

    OpenUrl
36. 36.↵
    1. Ochs RL,
    2. Muro Y,
    3. Si Y,
    4. Ge H,
    5. Chan EK,
    6. Tan EM

    . Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000;105:1211–20.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Mahler M,
    2. Hanly JG,
    3. Fritzler MJ

    . Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2012;11:642–5.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Marlet J,
    2. Ankri A,
    3. Charuel JL,
    4. Ghillani-Dalbin P,
    5. Perret A,
    6. Martin-Toutain I,
    7. et al.

    Thrombophilia associated with anti-DFS70 autoantibodies. PLoS One 2015;10:e0138671.

    OpenUrlCrossRefPubMed